Tech Company Financing Transactions

Juventas Therapeutics Funding Round

Private investors participated in a $1.3 million funding round for Juventas Therapeutics. This VC investment round closed on 10/5/2017.

Transaction Overview

Announced On
10/5/2017
Transaction Type
Debt
Amount
$1,311,202
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 46 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3615 Superior Ave. 4403B
Cleveland, OH 44114
USA
Email Address
Overview
Juventas Therapeutics is a privately held biotechnology company developing a pipeline of regenerative therapies to treat life--threatening diseases. The company's lead product, Stromal--cell Derived Factor 1 (SDF--1), has been shown to protect and repair tissue following organ--damage in a broad range of pre--clinical disease models.
Profile
Juventas Therapeutics LinkedIn Company Profile
Social Media
Juventas Therapeutics Company Twitter Account
Company News
Juventas Therapeutics News
Facebook
Juventas Therapeutics on Facebook
YouTube
Juventas Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Rahul Aras
  Rahul Aras LinkedIn Profile  Rahul Aras Twitter Account  Rahul Aras News  Rahul Aras on Facebook
Chief Medical Officer
Matthew Pollman
  Matthew Pollman LinkedIn Profile  Matthew Pollman Twitter Account  Matthew Pollman News  Matthew Pollman on Facebook
VP - Operations
Michael Fitzgerald
  Michael Fitzgerald LinkedIn Profile  Michael Fitzgerald Twitter Account  Michael Fitzgerald News  Michael Fitzgerald on Facebook
VP - Product Management
Joseph Pastore
  Joseph Pastore LinkedIn Profile  Joseph Pastore Twitter Account  Joseph Pastore News  Joseph Pastore on Facebook


 

 

Browse more venture capital transactions:

Prev: 10/5/2017: Bluecore venture capital transaction
Next: 10/5/2017: Energage venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on funding rounds that are announced publicly. VC investment data records reported here come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary